Birchbrook’s CRISPR Therapeutics CRSP Stock Holding History

Birchbrook’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$19.6K	Sell	355 -50	-12%	-$2.7K	0.01%	167
2026 Q2	$22.1K	Hold	405	–	–	0.01%	166
2026 Q1	$19.3K	Hold	405	–	–	0.01%	164
2025 Q4	$21.2K	Sell	405 -645	-61%	-$38.6K	0.01%	169
2025 Q3	$68.1K	Hold	1,050	–	–	0.04%	115
2025 Q2	$51.1K	Buy	1,050 +1,000	+2,000%	+$38.7K	0.03%	124
2025 Q1	$1.7K	Hold	50	–	–	﹤0.01%	238
2024 Q4	$1.97K	Hold	50	–	–	﹤0.01%	257
2024 Q3	$2.35K	Hold	50	–	–	﹤0.01%	236
2024 Q2	$2.7K	Hold	50	–	–	﹤0.01%	235
2024 Q1	$3.41K	Hold	50	–	–	﹤0.01%	237
2023 Q4	$3.13K	Buy	+50	New	+$2.76K	﹤0.01%	259

Other funds holding CRSP

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Slow Capital Greenbrae, California $890M AUM 40.96% 1-Year Est. Return

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return

NTV Asset Management Charleston, West Virginia $1.08B AUM 23.94% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Birchbrook's CRSP Position: Q3 2026 in Review

Birchbrook reduced its CRISPR Therapeutics (CRSP) stake by 12% in Q3 2026, selling an estimated $2.7K and leaving 355 shares worth $19.6K. The position accounts for 0.01% of the portfolio, ranked #167.

Birchbrook first reported a position in CRSP in Q4 2023 and has held it in 12 quarters since. The position peaked at $68.1K in Q3 2025. 159 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

Birchbrook held 355 shares of CRISPR Therapeutics worth $19.6K as of Q3 2026.
Birchbrook sold 50 CRISPR Therapeutics shares in Q3 2026, an estimated $2.7K.
CRISPR Therapeutics made up 0.01% of Birchbrook's portfolio in Q3 2026, its #167 holding.
Birchbrook first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 12 quarters since.
Birchbrook's CRISPR Therapeutics position peaked at $68.1K in Q3 2025.
159 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Birchbrook's 13F filing for Q3 2026, filed 14 Oct 2026.